2157 — Lepu Biopharma Co Balance Sheet
0.000.00%
- HK$21.22bn
- HK$21.60bn
- CNY367.79m
Annual balance sheet for Lepu Biopharma Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 754 | 205 | 669 | 490 | 465 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.117 | 0.073 | 25.3 | 55.2 | 81.8 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 843 | 314 | 813 | 677 | 646 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 770 | 978 | 1,039 | 1,087 | 1,051 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 2,424 | 2,082 | 2,529 | 2,384 | 2,281 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 382 | 549 | 844 | 900 | 1,044 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 950 | 1,245 | 1,628 | 1,487 | 1,578 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 1,474 | 837 | 901 | 897 | 703 |
| Total Liabilities & Shareholders' Equity | 2,424 | 2,082 | 2,529 | 2,384 | 2,281 |
| Total Common Shares Outstanding |